We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · October 24, 2019

Gefitinib ± Pemetrexed as First-Line Treatment in Nonsquamous NSCLC With EGFR Mutation

Journal of Thoracic Oncology


Additional Info

Disclosure statements are available on the authors' profiles:

Journal of Thoracic Oncology
A Randomized Phase 2 Study of Gefitinib With or Without Pemetrexed as First-Line Treatment in Nonsquamous Non-Small Cell Lung Cancer With EGFR Mutation: Final Overall Survival and Biomarker Analysis
J Thorac Oncol 2019 Oct 09;[EPub Ahead of Print], JC Yang, Y Cheng, H Murakami, P Yang, J He, K Nakagawa, JH Kang, J Kim, RR Hozak, TS Nguyen, WL Zhang, S Enatsu, T Puri, M Orlando

Further Reading